Human placenta-derived adherent cells (PDAC®) is a novel, culture-expanded cell population derived from healthy, full-term human placental tissue. The cells are plastic-adherent and undifferentiated in vitro. PDAC are genetically stable, displaying a normal diploid chromosome count, and a normal karyotype and exhibit normal senescence after prolonged culture periods. We are developing PDACs for the treatment of various indications in the Inflammatory and Immunology (I&I) space.

PDACs are characterized by CD34-, CD10+, CD105+ and CD200+ phenotype, with moderate expression of human leukocyte antigen (HLA) Class I and undetectable levels of HLA Class II.

In vitro studies showed that PDAC cells exhibit immune-modulatory properties – they suppress effector cell function, promote tolerogenic immune phenotype, and reduced pro-inflammatory cytokine secretion. PDAC cells also possess regenerative and pro-angiogenic properties demonstrated through the secretion of several mitogens and angiogenic factors.

In vivo, we have demonstrated immune-modulatory properties of PDAC cells can autoimmunity using encephalomyelitis (EAE) mouse model, anti-inflammatory activity in rat perineural inflammation neuritis model, anti-fibrotic effect in mice lung fibrosis model and neuroprotection and pro-neurogenesis in rodent stroke models.